TEL: 044-952-0102


Protein Kinase Inhibitors in Oncology: Analytical Tool

発行 BioSeeker Group AB 商品コード 166080
出版日 ページ情報 英文
納期: 即日から翌営業日
本日の銀行送金レート: 1USD=107.65円で換算しております。
Back to Top
分析ツール:癌治療におけるプロテインキナーゼ阻害剤 Protein Kinase Inhibitors in Oncology: Analytical Tool
出版日: 2018年12月05日 ページ情報: 英文



  • <調査報告書> 癌におけるプロテインキナーゼ治療(商品コード:103311)
    • 第1章 エグゼクティブサマリー
    • 第2章 癌について
    • 第3章 調査手法
    • 第4章 目次
    • 第5章 イントロダクション
    • 第6章 治療効果を最大限にし投資回収率を上げるための治療標的
      • 薬剤リポジショニング
      • プロテインキナーゼ治療標的
      • 癌ゲノムプロジェクトとプロテインキナーゼ治療標的
      • プロテインキナーゼ治療における構造ベースの薬剤デザイン
      • 特定されたプロテインキナーゼ治療標的間の相互作用
      • 薬剤と標的とのインテラクトーム
      • 経路分析
    • 第7章 新製品の台頭
      • 終了した薬剤標的プロファイル
      • 登録前上市準備段階
      • 第3相治験
      • 第2相治験
      • 第1相治験
      • 前治験
      • 癌治療用プロテインキナーゼ薬剤のプロファイル
    • 第8章 化合物戦略:化合物別プロテインキナーゼ治療薬の競合ベンチマーキング
      • 小分子
      • ペプチド・プロテイン薬剤
      • 抗体、抗体様構造
      • 核酸治療
      • 細胞・遺伝子治療
      • プロテインキナーゼ治療薬の近似性競合
      • プロテインキナーゼ治療標的のサブセルラーローカリゼーションに基づく化合物戦略
    • 第9章 プロテインキナーゼ治療薬の癌への適応
      • 急性リンパ性白血病
      • 急性骨髄性白血病
      • 副腎癌
      • B細胞リンパ腫
      • 基底細胞癌
      • 良性前立腺過形成
      • 胆道癌 他
    • 第10章 ポートフォリオプランニング
    • 第11章 免責事項
    • 第12章 薬剤インデックス
    • 第13章 企業インデックス
  • <データベース>癌治療のためのプロテインキナーゼ阻害剤パイプライン(商品コード:171785)
    • 治験責任医師
    • 薬剤名および異名
      • 商標名
      • ジェネリック薬
      • コードネーム
    • 開発段階
      • 開発中の520の薬剤最新動向
      • 上市済み
      • 登録済み
      • 登録前
      • 第3相
      • 第2相
      • 第1相
      • 前臨床
      • データなし
      • 中断
      • 中止
    • 適応
    • 標的
      • 187の標的を45に分類
    • 標的発現プロファイル
    • 経路
    • メカニズム
    • 化合物
    • 薬剤プロファイル
      • 薬剤名
      • 治験担当医師およびパートナー
      • 標的および標的の分子機能
      • 標的の部位
      • 標的発現プロファイル
      • 標的シグナリング経路
      • メカニズム
      • 開発プロジェクト
      • 薬剤解説
      • 化合物データ
      • 特許データ
      • ビジネスおよび市場
      • 第3相データ
      • 第2相データ
      • 第1相データ
      • 臨床前データ
      • ライセンシング情報
    • 応用特性
    • システム要件
      • Operating system: Windows (2000/XP/Vista/7/8) for Mac Users the service is only available online
      • Browser Application (Internet Explorer, Firefox, Chrome, Safari)
      • Internet access (to access related internet resources)


Product Code: BSG21823

Kinase-targeted cancer therapies became really big with imatinib (Gleevec), a landmark drug that has vastly improved the outcomes of patients with chronic myelogenous leukemia. With the human genome encoding 538 protein kinases and many of these kinases being associated with human cancer initiation and progression, this field carries a lot of promise for more treatment successes in the future.

Protein Kinase Inhibitors in Oncology: Analytical Tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your PKI drug surveillance and intelligence, allowing you to power your decision making and advance your own interests.

Keeping you "In the know"

Simply put, our mission is to fuel your knowledge of oncology, to make you the first to know about very early technologies and startups, emerging clinical trial results, drug approvals and the ever-changing competitive landscape. Protein Kinase Inhibitors in Oncology: Analytical Tool achieves this by continuously scanning development in PKI and reporting:

  • Deals & Collaborations
  • New technologies/drugs (emerging from patents, grants, abstracts (see Conference Coverage) etc.)
  • Funding/Grants/IPOs
  • Filings & Approvals
  • Latest Clinical Trial Development & Results
  • Newly launched clinical trials
  • Conference Coverage of the world's twelve leading meetings in oncology*
  • Quarterly & Annual Reporting

This puts you in control of most, if not all, day-to-day developments in your field while also benefiting from one of the most comprehensive commercial pipeline review & competitive assessment tools available on the market today! Identify, prioritize, and lead scientific assessment of oncology opportunities and competition by multiple factors such as:

  • Emerging Technologies
  • Target Novelty
  • Recent Funding
  • Early & Late Stage Pipeline
  • Biomarker/Companion Diagnostic Development (featured below)
  • Entered Deals & Alliances
  • Conference surveillance of world leading cancer meetings (featured below)
  • Combination Therapy Choices (featured below)
  • Outcome of Clinical Trials
  • Indication Selection & Expansion Choices
  • Drug Repositioning Opportunities

For 20 years we have supported better decision making across the oncology drug development industry. Your Protein Kinase Inhibitors in Oncology: Analytical Tool is based on two decades of proven methodology and transforms your computer's desktop into a high capacity workbench within your area of choice. Even before launching this tool you have already eliminated the hundreds of hours of work needed to discover, process and piece together the thousands of sources that our team of oncology dedicated and highly experienced contents specialists have done on your behalf.

Your Protein Kinase Inhibitors in Oncology: Analytical Tool covers more than 508 companies plus partners who are today developing 1668 PKI drugs where of 940 are in active development in cancer across 322 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.

Let our expertise work for you

With a simple point and click interface you can navigate the environment of current development, drill down into specific areas such as ongoing combination trials, biomarker analysis, selected scientific abstracts etc. and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts). Any analysis generated by you is packed with presentation-ready graphs and tables to use in your reports and presentations.

Your key to access development at the world-leading cancer meetings

The Protein Kinase Inhibitors in Oncology: Analytical Tool is continuously updated according to twelve of the world's most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia). If you are not able to attend any of the conference(s) in person, this Analytical Tool ensures that you are not missing out on the important take home messages you need to know about.

Run combination therapy analysis like no other

The Protein Kinase Inhibitors in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.

Unparalleled biomarker surveillance

We also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and usage of more than 1,000 biomarkers across tens of thousands of cancer clinical trials.

Support and inspiration at your finger-tips

You also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools.

A tool to grow with and keep you informed

Unlike a static report which just represents a particular snapshot in time, all of the Analytical Tools come with one year of online access to twice-weekly updates in both contents and features, pipeline alerts and online support etc. You can choose to renew your access to these updates and support on a yearly basis or go over to our industry leading full service platform covering all oncology drug development, 1stOncology.

System Requirements

  • Browser Application (Supports: Internet Explorer, FireFox, Chrome and Safari))
  • Internet access
Back to Top